HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)

[1]  J. Margolick,et al.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study , 2001, AIDS.

[2]  J. Margolick,et al.  Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.

[3]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[5]  R. Greenblatt,et al.  Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. , 2000, American journal of epidemiology.

[6]  D. Vergani,et al.  Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms , 2000, Hepatology.

[7]  M. Stoll,et al.  Immune reconstitution syndromes in human immuno-deficiency virus infection following effective antiretroviral therapy. , 2000, Immunobiology.

[8]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[9]  M. Lindegren,et al.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[11]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[12]  H. Margolis,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[13]  S. Lawrence,et al.  Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[15]  B. Yip,et al.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  V. Vullo,et al.  Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. , 1998, AIDS.

[17]  S. Darby,et al.  Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.

[18]  C. J. Chen,et al.  Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. , 1997, American journal of epidemiology.

[19]  D. Cooper,et al.  Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor , 1997, The Lancet.

[20]  R. Tedder,et al.  Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection , 1997, AIDS.

[21]  K. O'rourke,et al.  The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. , 1996, Journal of clinical gastroenterology.

[22]  London Wt,et al.  The epidemiology of hepatitis viruses B, C, and D. , 1996 .

[23]  M. Alter,et al.  Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. , 1994, The Journal of infectious diseases.

[24]  J. Villeneuve,et al.  A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. , 1994, Gastroenterology.

[25]  G. Beebe,et al.  Mortality follow‐up of the 1942 epidemic of hepatitis B in the U.S. Army , 1993, Hepatology.

[26]  D. Vlahov,et al.  Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. , 1991, American journal of epidemiology.

[27]  S. Hadler,et al.  Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. , 1991, The Journal of infectious diseases.

[28]  R. Perrillo,et al.  Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. , 1990, Gastroenterology.

[29]  B. McMahon,et al.  Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. , 1990, Archives of internal medicine.

[30]  R. Palmiter,et al.  Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. , 1990, Science.

[31]  B. Donovan,et al.  The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. , 1989, The Journal of infectious diseases.

[32]  C. Horsburgh,et al.  Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. , 1988, The American journal of gastroenterology.

[33]  R. Brookmeyer,et al.  Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. , 1987, American journal of epidemiology.

[34]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[35]  E. Schiff,et al.  A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. , 1987, The New England journal of medicine.

[36]  A. Zuckerman,et al.  FULMINANT HEPATIC FAILURE IN LEUKAEMIA AND CHORIOCARCINOMA RELATED TO WITHDRAWAL OF CYTOTOXIC DRUG THERAPY , 1975, The Lancet.

[37]  A. Skulberg,et al.  Letter: Occupational hazard of halothane. , 1974, Lancet.

[38]  F. Callea,et al.  Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.

[39]  Clive Osmond,et al.  Statistical Methods in Cancer Research, Vol. 2, the Design and Analysis of Cohort Studies , 1990 .

[40]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.